NCT06262776 - Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

ImmunosuppressionVaccine Response Impaired

Interventions

BIOLOGICAL

Recombinant zoster vaccine adjuvanted (SHINGRIX)

2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.

Trial Locations (1)

RECRUITING

Royal Adelaide Hospital, Adelaide

All Listed Sponsors

collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

University of Adelaide

OTHER

collaborator

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

lead

Central Adelaide Local Health Network Incorporated

OTHER_GOV